CEA TRFIA (time-resolved fluoroimmunoassay) kit based on IMB (immunomagnetic beads)

A time-resolved fluorescence and immunoassay technology, applied in the fields of nanobiology and bioanalytical chemistry, can solve the problem that tumor-associated antigens have not been reported in the literature, and achieve the effects of shortening the reaction time, widening the range of the standard curve, and improving the detection sensitivity
CN102507947BActive Publication Date: 2015-05-27GUANGZHOU BIOKEY HEALTH TECH CO LTD
7 Cites 1 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
GUANGZHOU BIOKEY HEALTH TECH CO LTD
Publication Date
2015-05-27

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention discloses a CEA TRFIA (time-resolved fluoroimmunoassay) kit based on IMB (immunomagnetic beads). The kit includes a calibrator, immunomagnetic beads connected with CEA antibodies, europium labeled CEA antibodies, an assay buffer solution, a cleaning solution and an enhanced solution. Through double antibody sandwich immunoreaction, IMB-CEA-europium labeled-CEA monoclonal antibody complexes are formed, IMB which adsorb CEA and supernate are separated through magnetic seperation and washed, the enhanced solution is added, and the value is measured through a time-resolved instrument. Besides the TRFIA technology, the invention further has the advantages as follows: through IMB enrichment and full diffusion of IMB in the solution, the combination superficial area is enlarged, the reaction time is greatly shortened, and the detection sensitivity is improved. IMB and antibodies are directionally connected through chemical groups, so that the consumption of paired antibodies is greatly reduced and the detection precision is improved. The technology realizes automation easily, and overcomes the problem that the traditional micropore plate type TRFIA technology can only carry out detection after samples are accumulated to a certain number, thereby realizing real-time sample detection.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention belongs to the fields of bioanalytical chemistry and nano-biotechnology, and in particular relates to a CEA time-resolved fluorescent immunoassay kit based on immunomagnetic beads. Background technique

[0002] Carcinoembryonic antigen (CEA) was first discovered by Gold and Freedman in 1965 from fetal and colon cancer tissues. The coding gene of CEA is located on chromosome 19, which is a polysaccharide-protein complex with a molecular weight of 22,000, 45% of which is protein. In general, CEA is synthesized by fetal gastrointestinal epithelial tissue, pancreas and liver cells. Usually, the CEA content increases within the first 6 months of pregnancy, and the serum level is already very low after birth. Under normal circumstances, CEA is metabolized by the gastrointestinal tract, but in a tumor state, CEA enters the blood and lymphatic circulation, causing an abnormal increase in serum CEA. At present, it is believed that CEA is widely...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More